News

Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…

A new artificial intelligence (AI) model that analyzes images of the eye can help accurately identify neuromyelitis optica spectrum disorder (NMOSD), a study shows. The model outperformed specialists when relying solely on eye images. When clinical data such as MRI scans and antibody tests were provided, the model’s accuracy…

Most people with neuromyelitis optica spectrum disorder (NMOSD) have impaired sleep quality and architecture — an individual’s cyclical sleep pattern, involving different stages — relative to healthy people, according to a new study from researchers in India. NMOSD patients were also found to have reductions in the volume of…

People with neuromyelitis optica spectrum disorder (NMOSD) are at a nine times higher risk of developing autoimmune rheumatic diseases, or those affecting the joints, muscles, or connective tissue, a South Korean study found. Connective tissue provides support, connection, and binding for tissues and organs. The findings align with a…

High levels of two proteins, called FAM3B and PF4V1, are associated with a reduced risk of neuromyelitis optica spectrum disorder (NMOSD), while elevated levels of two other proteins, called CLEC11A and SERPINA1, are linked to increased odds of developing the immune system disease. These are the findings of a…

Rituximab and mycophenolate mofetil (MMF) may be the most effective off-label options for neuromyelitis optica spectrum disorder (NMOSD) patients who are unable to access approved therapies, often due to high costs or limited availability, according to a study in China. The study compared the safety and efficacy of four immunosuppressive…

Infection rates were consistently lower in adults with neuromyelitis optica spectrum disorder (NMSOD) treated with Enspryng (satralizumab-mwge) over other immunosuppressive therapies, according to long-term data from clinical trials and real-world settings. “This analysis provides reassurance that the [Enspryng] safety profile observed in patients with NMOSD in a clinical…

People who develop neuromyelitis optica spectrum disorder (NMOSD) at 50 years or older are significantly more likely to experience worse recovery from relapses and faster disability progression than those with early-onset disease, a study in Germany showed. These increased risks were seen despite comparable relapse rates, more intensive relapse…

Treatment with Enspryng (satralizumab) allows nearly all neuromyelitis optica spectrum disorder (NMOSD) patients to remain free of relapses after six months, with many reducing their use of corticosteroids and other immunosuppressants. Nearly one-third of patients were able to stop corticosteroids, which can cause serious side effects when used…

Smoking is associated with a significantly higher risk of residual disability from onset attack in neuromyelitis optica spectrum disorder (NMOSD) patients with antibodies against the AQP4 protein, a new study showed. Similar results were seen for the presence of nonsmoking vascular risk factors (VRF) such as high blood pressure,…